Methods and goals for the use of in vitro and in vivo chemosensitivity testing

Molecular Biotechnology

Volumn 35, Issue 2, 2007, Pages 185-197

  Blumenthal, Rosalyn D ^a   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

Dose response curve; Imaging; Metabolic assays; Molecular markers; Proliferation assays

Indexed keywords

BIOASSAY; BIOMARKERS; MEDICAL IMAGING; METABOLISM; PATIENT MONITORING; TUMORS;

DOSE RESPONSE CURVE; METABOLIC ASSAYS; MOLECULAR MARKERS; PROLIFERATION ASSAYS;

CHEMOSTATS;

BIOLOGICAL MARKER;

APOPTOSIS; BIOASSAY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CORRELATION ANALYSIS; CROSS RESISTANCE; DIAGNOSTIC ACCURACY; GENOMICS; HUMAN; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEOMICS; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; TECHNIQUE; TUMOR CLASSIFICATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENOMICS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR STEM CELL ASSAY;

EID: 34247362027     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02686104     Document Type: Review

References (96)

1. Nagourney, R. A. 2006. Ex vivo programmed cell death and the prediction of response to chemotherapy. Curr. Treat. Options Oncol. 7, 103-110.
2. Chow, K. U., Nowak, D., Kim, S. Z., et al. 2006. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol. Res. 53, 49-61.
3. Noguchi, K., Iwahashi, M., Tani, M., et al. 2005. Evaluation of chemosensitivity testing with highly purified tumor cells in 435 patients with gastric carcinoma using an MTT assay. Anticancer Res. 25, 931-937.
4. Trojan, J., Kim, S. Z., Engels, K., Kriener, S., Mitrou, P. S., and Chow, K. U. 2005. In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anticancer Drugs 16, 87-91.
5. Kaspers, G., Zwaan, C., Pieters, R., and Veerman, A. 1999. Cellular drug resistance in childhood acute myeloid leukemia. A mini-review with emphasis on cell culture assays. Adv. Exp. Med. Biol. 457, 415-421.
6. Robert, J. 1999. Chemosensitivity Testing: Prediction of response to anticancer drugs using in vitro assays. Electronic J. Oncol. 2, 198-210.
7. Bellamy, W. 1992. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 44, 690-708.
8. Gercel-Taylor, C., Ackermann, M., and Taylor, D. 2001. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing. Anticancer Res. 21, 2761-2768.
9. Von Hoff, D., Clark, G., Stogilll, B., et al. 1983. Prospective clinical trial of a human tumor cloning system. Cancer Res. 43,
10. Engblom, P., Rantanen, V., Kulmala, J., and Grenman, S. 1996. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with a 96-well plate clonogenic assay. Anticancer Res. 16, 1743-1747.
11. Fiebig, H. H., Maier, A., and Burger, A. M. 2004. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 40, 802-820.
12. Dollner, R., Granzow, C., Neudert, M., and Dietz, A. 2006. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res, 26, 1651-1655.
13. Weisenthal, L., Marsden, J., Dill, P., and Macaluso, C. 1983. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 43, 749-757.
14. Kern, D., Drozemuller, C., Kennedy, M., et al. 1985. Development of a miniaturized improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res. 45, 5436-5441.
15. Sondak, V., Bertelson, C., Tanigawa, N., et al. 1984. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res. 46, 1725-1728.
16. Kobayashi, H., Higashiyami, M., Minamigawa, K., et al. 2001. Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantitation. Jpn. J. Cancer Res. 92, 203-210.
17. Kangas, L., Gronroos, M., and Nieminen, A. 1984. Bioluminesence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med. Biol. 62, 338-343.
18. Csoka, K., Larsson, R., Tholander, B., Gerdin, E., de la Torre, M., and Nygren, P. 1994. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol. Oncol. 54, 163-170.
19. Rubinstein, L., Shoemaker, R., Pacell, K., Simon, R., and Tosini, S. 1990. Comparison of an in vitro anticancer drug screening data generated with a tetrazoilum assay versus a protein assay against a diverse panel of human tumor cells lines. J. Natl. Cancer Inst. 82, 1113-1118.
20. Krasna, L., Netikova, I., Chaloupkova, A., et al. 2003. Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens. Anticancer Res. 23, 2593-2599.
21. Sevin, B., Peng, Z., Perras, J., Panalver, G., and Averette, H. 1988. Application of an ATP bioluminescence assay in human tumor chemosensitivity testing. Gynecol. Oncol. 31, 191-204.
22. Andreotti, P., Cree, I., Kurbacher, C., et al. 1995. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res, 55, 5276-5282.
23. Steff, A., Fortin, M., Arguin, C., and Hugo, P. 2001. Detection of a decrease in green fluorescent protein fluorescence forthe monitoring of cell death: an assay amenable to high-throughput screening technologies. Cytometry 45, 237-243.
24. Waldenmaier, D. S., Babarina, A., and Kischkel, F. C. 2003. Rapid in vitro chemosensitivity analysis of human colon tumor cell lines. Toxicol. Appl. Pharmacol. 192, 237-245.
25. Otto, A. M., Brischwein, M., Niendorf, A., Henning, T., Motrescu, E., and Wolf, B. 2003. Microphysiological testing for chemosensitivity of living tumor cells with multiparametric microsensor chips. Cancer Detect. Prev. 27, 291-296.
26. Vistica, D., Skehan, P., Scudiero, D., et al. 1991. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res, 51, 2515-2520.
27. Sargent, J. and Taylor, C. 1989. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukemia. Brit. J. Cancer 60, 206-210.
28. Ross, D. D., Joneckis, C. C., Ordonez, J. V., et al. 1989. Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res. 49, 3776-3782.
29. Proffitt, R. T., Tran, J. V., and Reynolds, C. P. 1996. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 24, 204-213.
30. Hoffman, R. 1991. Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3, 86-92.
31. Singh, B., Li, R., Xyu, L., et al. 2002. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24, 437-442.
32. Meitner, P. 1991. The fluorescence cytoprint assay: a new approach to in vitro chemosensitivity testing. Oncology 5, 75-81.
33. Kern, D. and Weisenthal, L. 1990. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using supra-pharmacologic drug exposures. J. Natl. Cancer Inst. 82, 582-588.
34. Haroun, R., Clatterbuck, R., Gibbons, M., et al. 2002. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J. Neurooncol, 58, 115-123.
35. Fenech, M. 2000. The in vitro micronucleus technique. Mutation Res. 455, 81-95.
36. Fruhauf, J. and Bosanquet, A. 1993. In vitro determination of drug response: A discussion of clinical applications. PPO Updates 7, 1-21.
37. Reynolds, C. P. and Maurer, B. J. 2005. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med. 110, 173-183.
38. Clarke, R. 1996. Human breast cancer cell line xenografts as models of brest cancer. the immunobiologies of recipient mice and the characteristics of several tumorigenic lines. Breast Cancer Res. Treat. 39, 69-86.
39. Hoffman, R. 1999. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs 17, 343-359.
40. Price, J. 1996. Metastasis from human breast cancer cell lines. Breast Cancer Res. Treat. 39, 93-102.
41. Konovalova, N., Iatchkovskaya, R., Ganieva, L., et al. 1991. Subrenal capsule assay of human tumor chemosensitivity. Neoplasma 38, 275-284.
42. Tomayko, M. and Reynolds, C. 1989. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154.
43. Heitjan, D., Manni, A., and Santen, R. 1993. Statistical analysis of in vivo tumor growth experiments. Cancer Res, 53, 6042-6050.
44. Gibbs, J., Slocum, H., Cao, S., and Rustum, Y. 1999. Image analysis for quantitation of solid tumor drug sensitivity. Int. J. Surg. Invest. 1, 133-138.
45. Kubota, K. 2001. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann. Nucl. Med. 15, 471-486.
46. Belhocine, T., Steinmetz, N., Hustinx, R., et al. 2002. Increased uptake of the apoptosis imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8, 2766-2774.
47. Mazurchuk, R., Glaves, D., and Raghavan, D. 1997. Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer. Clin. Cancer Res. 3, 1635-1641.
48. Nakanishi, H., Mochizuki, Y., Kodera, Y., et al. 2003. Chemosensitivity of peritoneal micrometastases as evaluated using green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci. 94, 112-118.
49. Ring, A., Smith, I. E., and Dowsett, M. 2004. Circulating tumour cells in breast cancer. Lancet Oncol. 5, 79-88.
50. Allard, W. J., Matera, J., Miller, M. C., et al. 2004. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897-6904.
51. Tewari, K. and Manetta, A. 1999. In vitro chemosensitivity testing and mechanisms of drug resistance. Curr. Oncol. Rep. 1, 77-84.
52. el-Deiry, W. S. 1997. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 9, 79-87.
53. Fan, S., el-Deiry, W., Bae, I., et al. 1994. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res, 54, 5824-5830.
54. Bosken, C., Wei, Q., Amos, C., and Spitz, M. 2002. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 94, 1091-1099.
55. Zunino, F., Perego, P., Pilotti, S., and Pratesi, G. 1997. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol. Ther. 76, 177-185.
56. Wang, Y., Ashkenazi, Y., and Bachrach, U. 1999. In vitro chemosensitivity of hematological cancers: Immunohistochemical detection of ornithine decarboxylase. Anticancer Drugs 10, 797-805.
57. Park, K., Rha, S., Kim, C., et al. 1998. Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. Int. J. Oncol. 13, 489-495.
58. Modrak, D., Rodriguez, M., Goldenberg, D., Lew, W., and Blumenthall, R. 2002. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int. J. Oncol. 20, 379-384.
59. Epstein, R. 1990. Drug-induced DNA damage and tumor chemosensitivity. J. Clin. Oncol. 8, 2062-2084.
60. Xia, F. and Powell, S. 2002. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin. Radiat. Oncol. 12, 296-304.
61. Manahan, K., Taylor, D., and Gercel-Taylor, C. 2001. Clonal heterogeneity of p53 mutations in ovarian cancer. Int. J. Oncol. 19, 387-394.
62. Granjean, F., Bremaud, L., Verdier, M., Robert, J., and Ratinaud, M. 2001. Sequential gene expression of P-glycoprotein (P-gp), multidrug resisatnce associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Anticancer Drugs 12, 247-258.
63. Michieli, M., Damiani, D., Ermacora, A., et al. 2000. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resisatnce-associaed protein (MRP) expression in acute promyelocytic leukemia. Br. J. Haematol. 108, 703-709.
64. Pallis, M., Turzanski, J., Langabeer, S., and Russell, N. 1999. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. Adv. Exp. Med. Biol. 457, 77-88.
65. Pall, G., Spitaler, M., Hofmann, J., Thaler, J., and Ludescher, C. 1997. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia 11, 1067-1072.
66. Singh, N. 2000. A simple method for accurate estimation of apoptotic cells. Exp. Cell Res. 256, 328-337.
67. Munshi, A., McDonnell, T., and Meyn, R. 2002. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol. 50, 46-52.
68. Maciorowski, Z., Klijanienko, J., Padoy, E., et al. 2001. Comparative image and flow cytometric TUNEL analysis of fine needle samples of breast carcinoma. Cytometry 46, 150-156.
69. Ogata, S., Okumura, K., and Taguchi, H. 2000. A simple and rapid method for the detection of poly(ADP-ribose) by flow cytometry. Biosci. Biotechnol. Biochem. 64, 510-515.
70. Nita, M., Nagawa, H., Tominago, O., et al. 1998. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br. J. Cancer 78, 986-992.
71. Smith, D., Gao, G., Zhang, X., Wang, G., and Dou, Q. 2000. Regulation of tumor cell apoptotic sensitivity during the cell cycle (review). Int. J. Mol. Med. 6, 503-507.
72. Sonneveld, P. 2000. Multidrug resistance in hematological malignancies. J. Intern. Med. 247, 521-534.
73. Staunton, J., Slonim, D., Coller, H., et al. 2001. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98, 10787-10792.
74. Bao, L. and Sun, Z. 2002. Identifying genes related to drug anticancer mechanisms using support vector machine. FEBS Lett. 521, 109-114.
75. McLeod, H. 2002. Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Rev. Anticancer Ther. 2, 113-119.
76. Amundson, S., Myers, T., Scudiero, D., Kitada, S., Reed, J., and Fornace, A. 2000. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110.
77. Alizadeh, A., Eisen, M., and Dasvis, R. 2000. Distinct types of diffuse large B-cell lympoma identified by gene expression profiling. Nature 403, 503-511.
78. Kihara, C., Tsunoda, T., Tanaka, T., et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res.. 61, 6474-6479.
79. Sotirious, C., Powles, T., Dowsett, M., et al. 2002. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3.
80. Stein, W. D., Litman, T., Fojo, T., and Bates, S. E. 2004. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res.. 64, 2805-2816.
81. Poland, J., Schadendorf, D., Lage, H., Schnolzer, M., Celis, J., and Siha, P. 2002. Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med. 40, 221-234.
82. Aschele, C., Debernardis, D., Casazza, S., et al.1999. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol. 17, 1760-1770.
83. Bachrach, U. and Wang, Y. 2003. In vitro chemosensitivity testin of hematological cancer patients: detection of ornithine decarboxylase. Rec. Results Cancer Res. 161, 62-70.
84. Konecny, G., Fritz, M., Untch, M., et al. 2001. Her-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res. Treat. 69, 53-63.
85. Yang, Q., Sakurai, T., Yoshimura, G., et al. 2000. Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C. Anticancer Res. 20, 4319-4322.
86. Yang, Q., Sakurai, T., Yoshimura, G., et al. 2000. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resisatnce to a series of anticancer drugs in breast carcinoma. Breast Cancer Res. Treat. 61, 211-216.
87. Rozan, S., Vincent-Salomon, A., Zafrani, B., et al. 1998. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer 79, 27-33.
88. Ginestier, C., Charafe-Jauffret, E., Bertucci, F., et al. 2002. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am. J. Pathol. 161, 1223-1233.
89. Jones, M., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L., Kohn, E., and Petricoin, E. R. 2002. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84.
90. Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Von Hoff, D. D., and Somerfield, M. R. 2004. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 22, 3631-3638.
91. Konecny, G., Untch, M., Slamon, D., et al. 2001. Drug interactions and cytotoxic effects of paclitaxel in combination withc arboplatin, epirubicin, gemcitabine, or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res. Treat. 67, 223-233.
92. Lopez, A., Pegram, M., Slamon, D., and Landaw, E. 1999. A model-based approach for assessing in vivo combination therapy interactions. Proc. Natl. Acad. Sci. USA 96, 13023-13028.
93. Heim, M., Eberhardt, W., Seeber, S., and Muller, M. 2000. Differential modulation of chemosensitivity to alkylkating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. 126, 198-204.
94. Kondratov, R., Komarov, P., Becker, Y., Ewenson, A., and Gudkov, A. 2001. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. USA 98, 14078-14083.
95. Henewisch-Becker, S. 1996. MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 10, S32-S38.
96. Levi, F., Giacchetti, S., Zidani, R., et al. 2001. Chremotherapy of colorectal cancer metastases. Hepatogastroenterology 48, 320-322.